PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
Endomagnetics Ltd.
Study ID
NCT06610539
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur using patient reported outcome measures.

Key Dates

Start date
Apr 22, 2025
Status verified
Mar 2026
Primary completion
Jun 30, 2028
Completion
Nov 30, 2028

Study Design

Enrollment
184 participants (estimated)

Primary Outcome Measure

Frequency of Magtrace-related skin discoloration as a proportion of patients receiving Magtrace, overall and by sub-sample [ Time Frame: post-op to 24 month follow-up ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
UNC, Lineberger Comprehensive Cancer CenterChapel HillNorth Carolina27599
Kristalyn Gallagher
VCU Massey Comprehensive Cancer CenterRichmondVirginia23298-

Find similar trials in Chapel Hill, NC

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
UNC, Lineberger Comprehensive Cancer Center· Chapel Hill, NCVCU Massey Comprehensive Cancer Center· Richmond, VA

Related Studies